- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
We are seeing lower lows in the indices as I write.
Sarepta Therapeutics' (SRPT) stock price target was increased at JMP Securities and RBC Capital on Wednesday due to the potential of Exondys, its Duchenne muscular dystrophy drug.
Because every stock has a unique personality that requires its own strategy.